Three component chimeric antisense oligonucleotides

Details Three component chimeric antisense oligonucleotides Three component chimeric antisense oligonucleotides

2005-10-25

2005-10-25

McGarry, Sean (Department: 1635)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

Method of regulating cell metabolism or physiology

C435S006120, C435S091100, C435S325000, C536S023100, C536S024300, C536S024310, C536S024330, C536S024500

Reexamination Certificate

active

06958239

ABSTRACT:
This invention relates to antisense oligonucleotides that target mRNAs in cells as substrates for the cellular enzyme RNase H and thereby cause specific degradation of the targeted mRNA. The oligonucleotides have three components: an RNase H activating region, a complementary region and 3′ and 5′ ends. The invention optimizes each of the components to resist intracellular nucleases, to increase hybridization to target mRNA, to specifically inactivate target mRNA in cells, and to decrease cytotoxicity.

REFERENCES:
patent: 5576208 (1996-11-01), Monia et al.
patent: 5582986 (1996-12-01), Monia et al.
patent: 5652356 (1997-07-01), Agrawal
patent: 5849902 (1998-12-01), Arrow et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: WO 89/05358 (1989-06-01), None
patent: WO 93/19203 (1993-09-01), None
patent: WO 94/02498 (1994-02-01), None
patent: WO 94/08053 (1994-04-01), None
Ma et al. Biotechnology Annual Review, vol. 5, 2000, pp. 155-196.
Jen et al. Stem Cells, vol. 18, 2000, pp. 307-319.
Green et al. J. Am. Coll. Surg., vol. 191, No. 1, Jul. 2000, pp. 93-105.
Agrawal et al. Molecular Medicine Today, vol. 6, Feb. 2000, pp. 72-81.
Bennett et al. , Chapter 2 from Methods in Molecular Medicine: Antisense Therapeutics (Ed. Agrawal), Humana. Press Inc. Totowa, N.J., 1996, pp. 13-46.
Branch, TIBS 23, pp. 45-50, Feb. 1998.
Flanagan et al., Nature Biotechnology, vol. 17, No. 1, pp. 48-52, Jan. 1999.
Marcus-Sekura et al. NAR, vol. 15, No. 14, pp. 5749-5763, 1987.
Milligan et al. J. of Medical Chemistry, vol. 36, No. 14, pp. 1923-1937, 1993.
De Mesmaeker et al.,Current Opinion in Structural Biology, 5:343-355 (1995).
Gerwitz et al.,Science, 93:3161-3163 (1996).
Moulds et al.,Biochemistry 34:5044-5053 (1995).
Monia et al., “Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression,”The Journal of Biological Chemistry, 268(19):14514-14522 (1993).
Agrawal, “Antisense oligonucleotides as antiviral agents,”Trends in Biotechnology, 10(5): 152-158 (1992).
Supplementary European Search Report for Application No. EP 97 94 3607, mailed Mar. 31, 2004.

Affiliated with

Also associated with

Rating

Three component chimeric antisense oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Three component chimeric antisense oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Three component chimeric antisense oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3449190